相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related 'physician-reported spondylitis'?
Juergen Braun et al.
ANNALS OF THE RHEUMATIC DISEASES (2022)
A Road Map of the Axial Spondyloarthritis Continuum
Sergio Schwartzman et al.
MAYO CLINIC PROCEEDINGS (2022)
IL-23 in axial spondyloarthritis and psoriatic arthritis: a good fit for biological treatment?
Fabiola Atzeni et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2022)
Validity of the Central Sensitization Inventory compared with traditional measures of disease severity in fibromyalgia
Fausto Salaffi et al.
PAIN PRACTICE (2022)
Improvement of Signs and Symptoms of Nonradiographic Axial Spondyloarthritis in Patients Treated With Secukinumab: Primary Results of a Randomized, Placebo-Controlled Phase III Study
Atul Deodhar et al.
ARTHRITIS & RHEUMATOLOGY (2021)
Central sensitization, illness perception and obesity should be considered when interpreting disease activity in axial spondyloarthritis
Stan C. Kieskamp et al.
RHEUMATOLOGY (2021)
IL-23 Inhibition in Ankylosing Spondylitis: Where Did It Go Wrong?
Dominique Baeten et al.
FRONTIERS IN IMMUNOLOGY (2021)
Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomised, placebo-controlled, phase 3 trial
James Cheng-Chung Wei et al.
ANNALS OF THE RHEUMATIC DISEASES (2021)
Anti-IL-17 Agents in the Treatment of Axial Spondyloarthritis
Fabiola Atzeni et al.
IMMUNOTARGETS AND THERAPY (2021)
The important role of central sensitization in chronic musculoskeletal pain seen in different rheumatic diseases
Mehmet Akif Guler et al.
CLINICAL RHEUMATOLOGY (2020)
Determining factors related to poor quality of life in patients with axial spondyloarthritis: results from the British Society for Rheumatology Biologics Register (BSRBR-AS)
Gary J. Macfarlane et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Efficacy and safety of secukinumab in Japanese patients with active ankylosing spondylitis: 24-week results from an open-label phase 3 study (MEASURE 2-J)
Mitsumasa Kishimoto et al.
MODERN RHEUMATOLOGY (2020)
Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study
Desiree van der Heijde et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
One-year effectiveness, retention rate, and safety of secukinumab in ankylosing spondylitis and psoriatic arthritis: a real-life multicenter study
Maria Sole Chimenti et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2020)
Drug Survival of Biologics in Treating Ankylosing Spondylitis: A Systematic Review and Meta-analysis of Real-World Evidence
Chia-Ling Yu et al.
BIODRUGS (2020)
Effects of ustekinumab on spondylitis-associated endpoints in TNFi-naive active psoriatic arthritis patients with physician-reported spondylitis: pooled results from two phase 3, randomised, controlled trials
Philip S. Helliwell et al.
RMD OPEN (2020)
Pain appraisal and quality of life in 108 outpatients with rheumatoid arthritis
Sara Larice et al.
SCANDINAVIAN JOURNAL OF PSYCHOLOGY (2020)
Pathophysiology and inhibition of IL-23 signaling in psoriatic arthritis: A molecular insight
Cuong Thach Nguyen et al.
CLINICAL IMMUNOLOGY (2019)
2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis
Michael M. Ward et al.
ARTHRITIS & RHEUMATOLOGY (2019)
Three Multicenter, Randomized, Double-Blind, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis
Atul Deodhar et al.
ARTHRITIS & RHEUMATOLOGY (2019)
Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen-Week Results From a Phase III Randomized, Double-Blind, Placebo-Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors
Atul Deodhar et al.
ARTHRITIS & RHEUMATOLOGY (2019)
Ankylosing spondylitis: etiology, pathogenesis, and treatments
Wei Zhu et al.
BONE RESEARCH (2019)
Patients with fibromyalgia rarely fulfil classification criteria for axial spondyloarthritis
Xenofon Baraliakos et al.
RHEUMATOLOGY (2018)
Neuroinflammation and Central Sensitization in Chronic and Widespread Pain
Ru-Rong Ji et al.
ANESTHESIOLOGY (2018)
Association of neuropathic-like pain characteristics with clinical and radiographic features in patients with ankylosing spondylitis
Jung-Hye Choi et al.
CLINICAL RHEUMATOLOGY (2018)
Neuropathic Pain Component in Axial Spondyloarthritis and the Influence on Disease Burden
Kevser Gok et al.
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY (2018)
A cellular and molecular view of T helper 17 cell plasticity in autoimmunity
Ralph Stadhouders et al.
JOURNAL OF AUTOIMMUNITY (2018)
Psychiatric adverse events during treatment with brodalumab: Analysis of psoriasis clinical trials
Mark G. Lebwohl et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)
Central sensitization is a risk factor for wound complications after primary total knee arthroplasty
Man Soo Kim et al.
KNEE SURGERY SPORTS TRAUMATOLOGY ARTHROSCOPY (2018)
IL-17 in the immunopathogenesis of spondyloarthritis
Leonie S. Taams et al.
NATURE REVIEWS RHEUMATOLOGY (2018)
Potential Mechanisms Underlying Centralized Pain and Emerging Therapeutic Interventions
Olivia C. Eller-Smith et al.
FRONTIERS IN CELLULAR NEUROSCIENCE (2018)
Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study
Dominique Baeten et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological diseasemodifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial
Desiree van der Heijde et al.
LANCET (2018)
Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation
Sophie Glatt et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Efficacy and Safety of Secukinumab 150 mg with and Without Loading Regimen in Ankylosing Spondylitis: 104-week Results from MEASURE 4 Study
Alan J. Kivitz et al.
RHEUMATOLOGY AND THERAPY (2018)
Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study
Joachim Sieper et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Regulation of autoantibody activity by the IL-23-TH17 axis determines the onset of autoimmune disease
Rene Pfeifle et al.
NATURE IMMUNOLOGY (2017)
Role of HLA-B27 in the pathogenesis of ankylosing spondylitis (Review)
Bin Chen et al.
MOLECULAR MEDICINE REPORTS (2017)
Central Sensitization Inventory as a Predictor of Worse Quality of Life Measures and Increased Length of Stay Following Spinal Fusion
E. Emily Bennett et al.
WORLD NEUROSURGERY (2017)
Pain and pain mechanisms in patients with inflammatory arthritis: A Danish nationwide cross-sectional DANBIO registry survey
S. Rifbjerg-Madsen et al.
PLOS ONE (2017)
Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3
Karel Pavelka et al.
ARTHRITIS RESEARCH & THERAPY (2017)
IL-17+ γδ T cells as kick-starters of inflammation
Pedro H. Papotto et al.
NATURE IMMUNOLOGY (2017)
Dysbiosis and zonulin upregulation alter gut epithelial and vascular barriers in patients with ankylosing spondylitis
Francesco Ciccia et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1/PSUMMIT-2)
Arthur Kavanaugh et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Role of podoplanin in the high interleukin-17A secretion resulting from interactions between activated lymphocytes and psoriatic skin-derived mesenchymal cells
M. Noack et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2016)
Secukinumab (AIN457) in the treatment of ankylosing spondylitis
Juergen Braun et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2016)
IL-17+CD8+T cells: Differentiation, phenotype and role in inflammatory disease
Ushani Srenathan et al.
IMMUNOLOGY LETTERS (2016)
Fluctuations in patient reported disease activity, pain and global being in patients with ankylosing spondylitis
Ivette Essers et al.
RHEUMATOLOGY (2016)
2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria
Frederick Wolfe et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2016)
Interaction among activated lymphocytes and mesenchymal cells through podoplanin is critical for a high IL-17 secretion
Melissa Noack et al.
ARTHRITIS RESEARCH & THERAPY (2016)
Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis
Dominique Baeten et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Major histocompatibility complex associations of ankylosing spondylitis are complex and involve further epistasis with ERAP1
Adrian Cortes et al.
NATURE COMMUNICATIONS (2015)
Intestinal Dysbiosis in Ankylosing Spondylitis
Mary-Ellen Costello et al.
ARTHRITIS & RHEUMATOLOGY (2015)
Proof of concept: enthesitis and new bone formation in spondyloarthritis are driven by mechanical strain and stromal cells
Peggy Jacques et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS)
Denis Poddubnyy et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Fibromyalgia in patients with axial spondyloarthritis: epidemiological profile and effect on measures of disease activity
Fausto Salaffi et al.
RHEUMATOLOGY INTERNATIONAL (2014)
Heterogeneous expression pattern of interleukin 17A (IL-17A), IL-17F and their receptors in synovium of rheumatoid arthritis, psoriatic arthritis and osteoarthritis: possible explanation for nonresponse to anti-IL-17 therapy?
Lisa G. M. van Baarsen et al.
ARTHRITIS RESEARCH & THERAPY (2014)
Endoplasmic Reticulum Degradation-Enhancing α-Mannosidase-like Protein 1 Targets Misfolded HLA-B27 Dimers for Endoplasmic Reticulum-Associated Degradation
David B. Guiliano et al.
ARTHRITIS & RHEUMATOLOGY (2014)
Disease-specific and inflammation-independent stromal alterations in spondylarthritis synovitis
Nataliya Yeremenko et al.
ARTHRITIS AND RHEUMATISM (2013)
Neuropathic Pain in Ankylosing Spondylitis: A Psychophysics and Brain Imaging Study
Qi Wu et al.
ARTHRITIS AND RHEUMATISM (2013)
TH17 Cell Induction and Effects of IL-17A and IL-17F Blockade in Experimental Colitis
Esben Gjerloff Wedebye Schmidt et al.
INFLAMMATORY BOWEL DISEASES (2013)
Levels of Circulating Th17 Cells and Regulatory T Cells in Ankylosing Spondylitis Patients with an Inadequate Response to Anti-TNF-α Therapy
Li Xueyi et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2013)
Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial
Dominique Baeten et al.
LANCET (2013)
Interleukin-23: as a drug target for autoimmune inflammatory diseases
Chunlei Tang et al.
IMMUNOLOGY (2012)
Association of serum interleukin-17 and interleukin-23 levels with disease activity in Chinese patients with ankylosing spondylitis
Wei-Sheng Chen et al.
JOURNAL OF THE CHINESE MEDICAL ASSOCIATION (2012)
Brodalumab, an Anti-Interleukin-17-Receptor Antibody for Psoriasis
Kim A. Papp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
A new definition of neuropathic pain
Troels S. Jensen et al.
PAIN (2011)
HLA-B27 Misfolding and the Unfolded Protein Response Augment Interleukin-23 Production and Are Associated With Th17 Activation in Transgenic Rats
Monica L. Delay et al.
ARTHRITIS AND RHEUMATISM (2009)
Overexpression of Interleukin-23, but Not Interleukin-17, as an Immunologic Signature of Subdinical Intestinal Inflammation in Ankylosing Spondylitis
Francesco Ciccia et al.
ARTHRITIS AND RHEUMATISM (2009)
The Kyoto protocol of IASP Basic Pain Terminology
John D. Loeser et al.
PAIN (2008)
The biopsychosocial approach to chronic pain: Scientific advances and future directions
Robert J. Gatchel et al.
PSYCHOLOGICAL BULLETIN (2007)
Serum IL-17, BMP-7, and bone turnover markers in patients with ankylosing spondylitis
Daniel Wendling et al.
JOINT BONE SPINE (2007)
IL-17A acts via p38 MAPK to increase stability of TNF-β-induced IL-8 mRNA in human ASM
S Henness et al.
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY (2006)
IL-23 enhances the inflammatory cell response in Cryptococcus neoformans infection and induces a cytokine pattern distinct from IL-12
MA Kleinschek et al.
JOURNAL OF IMMUNOLOGY (2006)
Expansion and enhanced survival of natural killer cells expressing the killer immunoglobulin-like receptor KIR3DL2 in spondylarthritis
AT Chan et al.
ARTHRITIS AND RHEUMATISM (2005)
The ER aminopeptidase ERAP1 enhances or limits antigen presentation by trimming epitopes to 8-9 residues
IA York et al.
NATURE IMMUNOLOGY (2002)
分享论文
